Resveratrol: from enhanced biosynthesis and bioavailability to multitargeting chronic diseases.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing preclinical mechanisms and clinical literature without systematic methodology
PubMed 30551481 · doi:10.1016/j.biopha.2018.11.075
What was done
This paper is a narrative review summarizing literature on resveratrol's biosynthesis, formulation strategies (such as bio-enhancers and nano-formulations) to address rapid metabolism and low bioavailability, molecular targets, and preclinical and clinical evaluations across chronic diseases including diabetes, cardiovascular conditions, neurodegenerative disorders, obesity, and cancer.
What was found
The abstract reports no numerical findings, effect sizes, or statistical metrics. It qualitatively summarizes that resveratrol acts on targets including sirtuins, adenosine monophosphate-activated protein kinase (AMPK), nuclear factor-kappa B (NF-κB), inflammatory cytokines, and antioxidant enzymes, thereby modulating processes such as mitochondrial biogenesis, apoptosis, angiogenesis, gluconeogenesis, and lipid metabolism.
Why it matters
It provides a high-level overview connecting methods for overcoming resveratrol's pharmacokinetic limitations with its molecular mechanisms and translational potential in chronic disease management.
Limits
The abstract contains no quantitative data or systematic review methodology. Narrative reviews carry inherent risks of publication and selection bias and do not perform structured critical appraisal or meta-analyses of the cited preclinical and clinical studies.
Cited by
- supports Animals do not produce polyphenols.